From Department of Enterprise, Trade and Employment
Published on
Last updated on
Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar TD, said:
"This is very positive news for Galway. These three Galway-based companies are working in high growth areas and their success shows the power of indigenous enterprise. Congratulations to the teams at Palliare, Ronspot and Venari Medical on these milestones, I look forward to seeing your continued growth."
Enterprise Ireland Regional Director Michael Brougham said:
"This has been a challenging year for businesses but many Irish exporting companies are continuing to grow and recruit talented, innovative employees. Palliare, Ronspot and Venari Medical are in the process of filling 30 new positions. Some have already been recruited and others will be filled in the coming months. This is really positive news for Galway and the western region. It proves that local innovation is having a global impact and these companies are competing and winning in international markets."
Caroline O’Dea of Managing Director of Palliare said:
"Further to recent US FDA clearance of our EVA15 insufflator product, we are now ramping up our manufacturing operation in preparation for a US launch early in 2021. We have also continued to grow our R&D capacity further to the company securing EU Horizon 2020 funding to complete development and release of the EndoTrap and LeakTrap surgical safety products. We are grateful for the support from Enterprise Ireland and Western development Commission as we progress into the market."
Michael Furey of Ronspot said:
"The support Ronspot has received from Enterprise Ireland has been crucial to our growth and for allowing us to make long term plans for servicing our market and international customers. As a native Galwegian I am passionate about developing the region and creating jobs and value. There is some amazingly talent to draw on and having the right supports in place helps it all fall into place."
Stephen Cox of Venari Medical said:
"We gained seed investment of €4.5 million this year to focus on preparation for First In Human clinical trials of our BioVena™ medical device next year. BioVena™ is a novel Class II catheter which uses the body’s natural response for the office-based treatment of chronic venous disease and venous leg ulcers, which affects 1 in 4 adults across the globe. We’ve recently added three talented R&D and Quality Engineers to our Galway team based at the new Innovation Hub at the Galway-Mayo Institute of Technology (GMIT). We are looking to expand again in 2021 with hires across R&D, Quality and Regulatory Affairs to bring BioVena™ through international regulatory approvals and commercialisation, and to further internal innovation in the development of new novel product lines for the treatment of unmet endovascular needs."
ENDS
For information contact Paul Daly, Press Office, Enterprise Ireland, 087-2235187 or paul.daly@enterprise-ireland.com